News
Curated oncology headlines from reputable sources, ranked by importance with Claude Opus 5.
News about: Stomach → cancer profile · × Clear filters
H. Pylori Exposure and Colorectal Cancer: The Evidence Grows
A risk-attribution modeling study based on estimates from 43 studies suggests that Helicobacter pylori exposure, long established as a cause of gastric cancer, may also contribute to colorectal cancer risk. The meta-analytic approach strengthens the epidemiological link between H. pylori infection and CRC, potentially expanding the cancer burden attributable to this bacterium. If confirmed in pros…
AI-supported decision-making after endoscopic resection of early gastric cancer: what the evidence shows
A review in Clinical Endoscopy examines how machine learning could support the decision made after endoscopic resection of early gastric cancer: proceed to additional gastrectomy with lymph node dissection, or observe. The clinical problem is real — lymph node metastasis occurs in roughly 5-10% of early gastric cancers, yet about 90% of patients sent for additional surgery turn out to have none, m…
'Practice-Changing' Data Expand Zanidatamab's Approval to Gastroesophageal Cancer
On 25 August 2026 the FDA approved zanidatamab (Ziihera) in the first-line treatment of unresectable locally advanced or metastatic HER2-positive gastric, gastro-oesophageal junction and oesophageal adenocarcinoma. In the registration trial HERIZON-GEA-01 (NCT05152147) the zanidatamab plus tislelizumab regimen extended median overall survival to 26.4 versus 19.2 months (HR 0.72; 95% CI 0.57-0.90; …
Disitamab Vedotin, Tislelizumab, and S-1 as First-Line Treatment for Advanced Gastric Cancer
First-line disitamab vedotin plus tislelizumab and S-1 in HER2-overexpressing advanced gastric or gastro-oesophageal junction adenocarcinoma achieved an objective response rate of 89.5% (95% CI 78.5-96.0), but at a cost in toxicity: grade 3 or worse treatment-related adverse events occurred in 64.9% of patients. In this single-arm phase 2 trial (n=57, median follow-up 28.2 months), median progress…
Perioperative tislelizumab plus chemotherapy for locally advanced gastric cancer: A randomized, prospective phase 2 trial
In patients whose tumours expressed tsMHC-II, adding tislelizumab to perioperative chemotherapy raised the major pathological response rate from 26.5% to 61.8% (p=0.003), meeting the prespecified primary endpoint — but this is a phase 2 trial in 136 patients, and the endpoint measured response in the resected specimen, not survival. No benefit was seen in the tsMHC-II-negative subgroup. Within the…
Trastuzumab Rezetecan in Human Epidermal Growth Factor Receptor 2–Expressing Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma and Colorectal Cancer: A Multicenter, Open-Label, Phase I Trial
A multicenter, open-label phase I trial published in the Journal of Clinical Oncology evaluated trastuzumab rezetecan, a novel antibody-drug conjugate targeting HER2, in patients with HER2-expressing advanced gastric or gastroesophageal junction adenocarcinoma and colorectal cancer. The study assessed safety, pharmacokinetics, and preliminary efficacy of this new ADC across multiple dose levels. T…
Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline Update
The American Society of Clinical Oncology (ASCO) has published an updated clinical practice guideline on immunotherapy and targeted therapy in advanced gastroesophageal cancer in the Journal of Clinical Oncology (April 2026). The update consolidates evidence from registrational trials and restates the recommended treatment sequences, biomarker-driven agent selection and combination regimens for pa…